Scholarlink

<p>Although toll like receptor (TLR) ligands are effective vaccine adjuvants, current synthetic TLR2 agonists suffer from low solubility, high cost, and detrimental effect towards protein antigen. Present study aimed to evaluate the immunostimulatory potential of five in-house PAM2CS lipopeptide-based TLR2 agonists (P1, P2, P6, P7 and P8) using peripheral blood mononuclear cells (PBMCs) from chicken (<i>n</i> = 4). Each agonist (10&#xa0;µg/mL) significantly upregulated the expression of interleukin (IL)-1 β and inducible nitric oxide synthase (iNOS) at 3&#xa0;h post-treatment with highest expression of IL-1β mRNA was observed with P1. There was a significant up-regulation of interferon (IFN)-β and IFN-γ by treatment with P1 at 3 and 12&#xa0;h intervals (<i>p</i> &lt; 0.05). Further, IL-4 mRNA was significantly upregulated with P1 and P7 treatment at 12 and 24&#xa0;h post-treatment respectively. Our results demonstrate that among all five agonists, P1 was the most effective in enhancing immune response genes expression including both type I and type II interferons, and in eliciting a balanced Th1 and Th2 responses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vitro evaluation of the immunostimulatory effects of PAM2CS lipopeptide-based TLR2 agonists in chicken peripheral blood mononuclear cells

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Maramreddy Darshini,
  • Saravanan Ramakrishnan,
  • Firdous Ahmed,
  • Deshkanwar S. Brar,
  • Arshpreet Kaur,
  • Deepak B. Salunke,
  • Vishal Chander,
  • Mithilesh Singh

摘要

Although toll like receptor (TLR) ligands are effective vaccine adjuvants, current synthetic TLR2 agonists suffer from low solubility, high cost, and detrimental effect towards protein antigen. Present study aimed to evaluate the immunostimulatory potential of five in-house PAM2CS lipopeptide-based TLR2 agonists (P1, P2, P6, P7 and P8) using peripheral blood mononuclear cells (PBMCs) from chicken (n = 4). Each agonist (10 µg/mL) significantly upregulated the expression of interleukin (IL)-1 β and inducible nitric oxide synthase (iNOS) at 3 h post-treatment with highest expression of IL-1β mRNA was observed with P1. There was a significant up-regulation of interferon (IFN)-β and IFN-γ by treatment with P1 at 3 and 12 h intervals (p < 0.05). Further, IL-4 mRNA was significantly upregulated with P1 and P7 treatment at 12 and 24 h post-treatment respectively. Our results demonstrate that among all five agonists, P1 was the most effective in enhancing immune response genes expression including both type I and type II interferons, and in eliciting a balanced Th1 and Th2 responses.